Related Experiment Video
Updated: Jun 15, 2026
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
[Utility and improvement of liposome injections AmBisome for clinical use]
Ikumi Sugiyama1, Kenzo Kudo, Katsuo Takahashi
1School of Pharmacy, Iwate Medical University, Japan.
Abstract:
We have studied AmBisome, which is amphotericin B containing liposomes, used in the treatment of mycosis. Any potential problems regarding the liposome formulation remain unknown because it is a new dosage form. AmBisome is useful in that it can decrease adverse reactions while maintaining a therapeutic effect. However, it is doubtful whether AmBisome is suitable in a busy clinical environment. For example, this formulation should be filtered with an established filter. We then carried out a questionnaire survey involving medical staff (doctors and nurses) to clarify the problems regarding the liposome formulation and its practical utilization. Most doctors were satisfied with the effect of AmBisome, but about 90% of nurses who had used the preparation answered that it was troublesome to use the filter. On the other hand, only 40% of doctors understood how to use the filter when AmBisome was made up; 14% of nurses also did not know how to use the filter. We thought this was because they were not shown how to use it; actually, 30% of doctors were shown the preparation method by medical representatives (MR), although no nurse received an explanation. The residual rate of amphotericin B on 100 used filter pieces differed 50-fold between the minimum and maximum values. AmBisome is effective as an antifungal agent. However, pharmaceutical companies must liaise with medical staff for its effective clinical use. We hope that such companies will have exchanges with medical staff to develop safe and simple medicines, and that liposomes will be effective for many patients.
Insights
AmBisome, a liposomal amphotericin B formulation for mycosis, shows efficacy but presents usability challenges. Medical staff, particularly nurses, find the required filtration process troublesome, indicating a need for improved training and simpler drug delivery systems.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Mycology
Context:
- AmBisome (liposomal amphotericin B) is a novel formulation for treating mycosis.
- Liposomal formulations offer potential for reduced adverse reactions and maintained therapeutic effects.
- Clinical application challenges for new drug delivery systems are not fully understood.
Purpose:
- To investigate the practical utilization and identify challenges associated with AmBisome liposomal formulation.
- To survey medical staff (doctors and nurses) regarding their experience with AmBisome preparation and use.
- To assess the impact of AmBisome's formulation on clinical workflow and staff understanding.
Summary:
- A questionnaire survey revealed that while doctors are satisfied with AmBisome's efficacy, approximately 90% of nurses found the required filtration process cumbersome.
- Significant knowledge gaps exist regarding the correct filter usage, with many doctors and nurses unaware of the procedure.
- Discrepancies in amphotericin B residual rates on filters suggest variability in preparation techniques, potentially linked to inadequate training, as only 30% of doctors received preparation guidance from medical representatives, and no nurses did.
Impact:
- Highlights the need for pharmaceutical companies to collaborate with healthcare professionals to improve AmBisome's clinical usability.
- Suggests that enhanced training and simpler preparation methods are crucial for the effective and safe administration of liposomal antifungal agents.
- Emphasizes the potential for liposomal drug delivery systems to benefit more patients if formulation and handling issues are addressed.
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
01:16Bioavailability Enhancement: Drug Solubility Enhancement
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention